Reinreude Wart Removaer

Description

The drug is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. It is imprinted with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the removal of common warts, which are characterized by a rough, cauliflower-like appearance.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly, and soaking in warm water for approximately 5 minutes may facilitate this process. After cleansing, the area must be dried completely. A small amount of the medication should then be applied to cover each wart, ensuring that it is allowed to dry. This application should be repeated twice daily as necessary, with treatment continuing for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated or infected skin, or on areas exhibiting redness, is not recommended due to the potential for exacerbating the condition.

Patients with diabetes or poor blood circulation should avoid use, as these conditions may impair healing and increase the risk of adverse effects.

Additionally, the product should not be applied to birthmarks, warts with hair growth, or moles, as these may present a risk of irritation or other complications.

Warnings and Precautions

The product is intended for external use only. It is imperative to avoid contact with the eyes. In the event of accidental exposure to the eyes, it is recommended to rinse thoroughly with water for a minimum of 15 minutes. Additionally, users should refrain from inhaling vapors associated with the product.

Healthcare professionals should advise patients who are pregnant or breastfeeding to consult with a qualified health professional prior to using this product to ensure safety for both the mother and child.

In cases of ingestion, immediate medical assistance should be sought, or the local poison control center should be contacted without delay.

Patients are advised to discontinue use and consult a healthcare provider if discomfort persists, ensuring that any adverse reactions are appropriately addressed.

Side Effects

Patients should be aware that the product is intended for external use only. It is crucial to avoid contact with the eyes; in the event of exposure, the affected area should be rinsed with water for 15 minutes. Additionally, patients are advised to avoid inhaling vapors associated with the product.

In the case of persistent discomfort, patients should discontinue use and consult a healthcare professional for further guidance.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Reinreude Wart Removaer (salicylic acid 17% wart removaer). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or a poison control center should be contacted.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, healthcare providers should carefully evaluate the potential risks and benefits when considering treatment for lactating patients.

Renal Impairment

There is no information available regarding renal impairment, dosage adjustments, special monitoring, or safety considerations for patients with reduced kidney function. Healthcare professionals should exercise caution and consider individual patient factors when treating patients with renal impairment, as specific guidelines or recommendations are not provided.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no information available regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure their safety while on treatment.

Overdosage

In the absence of specific information regarding overdosage in the provided sections of the Summary of Product Characteristics (SPL), healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdosage.

Recommended Actions In the event of an overdosage, it is essential for healthcare providers to assess the patient's clinical status and initiate appropriate supportive care. Monitoring of vital signs and symptomatic treatment should be implemented as necessary.

Potential Symptoms While specific symptoms of overdosage are not detailed, healthcare professionals should remain vigilant for any unusual or severe reactions that may arise, given the pharmacological profile of the medication.

Management Procedures In the absence of detailed overdosage information, healthcare professionals are encouraged to consult local poison control centers or toxicology experts for guidance on management strategies tailored to the individual case. It is also advisable to report any overdosage incidents to the relevant regulatory authorities to enhance the understanding of the drug's safety profile.

Overall, the lack of specific overdosage data underscores the importance of careful dosing and monitoring in clinical practice.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical help or contact a poison control center if the product is swallowed.

Patients should be informed that the product should not be applied to irritated or infected skin, or to areas that are reddened. Additionally, it should not be used on birthmarks, warts with hair growth, or moles.

Healthcare providers should instruct patients to discontinue use and consult a doctor if discomfort persists after application.

For patients who are pregnant or breastfeeding, it is essential to recommend consulting a health professional before using the product.

Storage and Handling

The product is supplied in a tube format, with specific handling and storage requirements to ensure its integrity and efficacy. It should be stored at room temperature, away from direct light exposure. To maintain the product's quality, it is essential to keep the tube tightly closed when not in use. Additionally, the product must be discarded after opening to prevent any potential degradation or contamination.

Additional Clinical Information

The product is administered topically, with a recommended application of a small amount to cover each wart, allowing it to dry. This process should be repeated twice daily as needed, for a maximum duration of 12 weeks.

Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. Additionally, patients are instructed to discontinue use and seek medical advice if discomfort persists.

Drug Information (PDF)

This file contains official product information for Reinreude Wart Removaer, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)